RNAC (Cartesian Therapeutics Inc) Long-Term Debt

Corporate emblem and logo of Selecta Biosciences Inc. (RNAC)

This daily price chart for Cartesian Therapeutics (RNAC) on the GURU.Markets platform reflects the asset's dynamics, where the indicator stands at 0.00. Successes in developing RNA-based treatments for cancer and autoimmune pathologies, along with anticipation of new alliances, are driving the increase in value. Cartesian Therapeutics (RNAC) is implementing temporal cell programming to minimize risks, while its R&D center is currently actively preparing reports on the second phase of key trials.

RNAC (Cartesian Therapeutics Inc) Company Long-Term Debt history from 02/21/2024 to 10/28/2026

Financial and market metric breakdowns for Cartesian Therapeutics Inc (RNAC)

- price and consensus price forecast:
Stock Quotes selectabio.com|RNAC - Price Target Chart
- market capitalization data:
Market Value Cartesian Therapeutics|RNAC - Total Company Value
- book capitalization data:
Net Assets per Single Share Cartesian Therapeutics|RNAC - Company Book Value|Market-to-Book Ratio selectabio.com|RNAC - Company Total Assets
- debt and liquidity data:
Debt to Capital Ratio Cartesian Therapeutics|RNAC - Long-Term Debt to Equity Ratio|Current Liabilities to Capital Selecta Biosciences Inc.|RNAC - Company Total Debt|Debt to Net Assets Ratio Cartesian Therapeutics|RNAC - Company Long-Term Debts|Company Current Liabilities Cartesian Therapeutics
Comprehensive company analysis:RNAC (selectabio.com)
Mass-produced product of Cartesian Therapeutics, Inc.

Cartesian Therapeutics (RNAC) invests in safe RNA-cell therapy to combat autoimmune pathologies. An analysis of the business's long-term debt allows for an assessment of the total volume of liabilities with a maturity of more than one year. The current value of 0.00 reflects the level of financial leverage used to fund costly research and development. Optimizing this burden minimizes default risk, confirming the stability of the company's fundamental model.

Competitor analysis for Cartesian Therapeutics

legendbiotech.com - Company Long-Term Liabilities|SANA (Sana Biotechnology, Inc.) - Company Long-Term Debt|AUTL: Long-Term Debt|Allogene Therapeutics Inc (ALLO) - Company Long-Term Debt|CLLS (Cellectis) - Company Long-Term Debt|Company Long-Term Debt CRBU (Caribou Biosciences)|Long-Term Debt instilbio.com|GNTA: Company Long-Term Debts|Long-Term Indebtedness centurytx.com IPSC|JSPR: Company Long-Term Liabilities|SNTI - Long-Term Debt|Company Long-Term Liabilities Adaptimmune Therapeutics PLC (ADAP)|CERO - Company Long-Term Loans and Borrowings|TCRT (alaunos.com) - Company Long-Term Debts|Achilles Therapeutics plc (ACHL) - Company Long-Term Liabilities|Company Long-Term Debts CRGX (Cargo Therapeutics)|Long-Term Debt PSTX|Company Long-Term Debt 2seventy bio, Inc. (TSVT)|Company Long-Term Debt GRCL (gracellbio.com)